JP2012508591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508591A5 JP2012508591A5 JP2011545349A JP2011545349A JP2012508591A5 JP 2012508591 A5 JP2012508591 A5 JP 2012508591A5 JP 2011545349 A JP2011545349 A JP 2011545349A JP 2011545349 A JP2011545349 A JP 2011545349A JP 2012508591 A5 JP2012508591 A5 JP 2012508591A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- isolated nucleic
- promoter
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims description 93
- 102000039446 nucleic acids Human genes 0.000 claims description 93
- 150000007523 nucleic acids Chemical class 0.000 claims description 93
- 210000004027 cell Anatomy 0.000 claims description 48
- 230000008672 reprogramming Effects 0.000 claims description 30
- 101150059079 EBNA1 gene Proteins 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 210000000130 stem cell Anatomy 0.000 claims description 18
- 230000003612 virological effect Effects 0.000 claims description 17
- 108020004414 DNA Proteins 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 16
- 230000003115 biocidal effect Effects 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 13
- 238000005215 recombination Methods 0.000 claims description 12
- 230000006798 recombination Effects 0.000 claims description 12
- 108700029231 Developmental Genes Proteins 0.000 claims description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 8
- 108091006047 fluorescent proteins Proteins 0.000 claims description 8
- 102000034287 fluorescent proteins Human genes 0.000 claims description 8
- 239000005090 green fluorescent protein Substances 0.000 claims description 8
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 6
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 6
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 6
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 6
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 6
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 6
- 101150086694 SLC22A3 gene Proteins 0.000 claims description 6
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 6
- 101150111214 lin-28 gene Proteins 0.000 claims description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 230000001605 fetal effect Effects 0.000 claims description 4
- 108010054624 red fluorescent protein Proteins 0.000 claims description 4
- 108700026220 vif Genes Proteins 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 229930193140 Neomycin Natural products 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 229930189065 blasticidin Natural products 0.000 claims description 3
- 229960004927 neomycin Drugs 0.000 claims description 3
- 229950010131 puromycin Drugs 0.000 claims description 3
- 229960002180 tetracycline Drugs 0.000 claims description 3
- 229930101283 tetracycline Natural products 0.000 claims description 3
- 235000019364 tetracycline Nutrition 0.000 claims description 3
- 150000003522 tetracyclines Chemical class 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 210000002308 embryonic cell Anatomy 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 11
- 239000002245 particle Substances 0.000 description 9
- 101100162210 Aspergillus parasiticus (strain ATCC 56775 / NRRL 5862 / SRRC 143 / SU-1) aflM gene Proteins 0.000 description 7
- 101100102500 Caenorhabditis elegans ver-1 gene Proteins 0.000 description 7
- 239000013598 vector Substances 0.000 description 6
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000000604 fetal stem cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11501308P | 2008-11-14 | 2008-11-14 | |
| US61/115,013 | 2008-11-14 | ||
| PCT/US2009/064488 WO2011071476A2 (en) | 2008-11-14 | 2009-11-13 | Compositions and methods for engineering cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012508591A JP2012508591A (ja) | 2012-04-12 |
| JP2012508591A5 true JP2012508591A5 (enExample) | 2013-05-23 |
Family
ID=43977926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011545349A Pending JP2012508591A (ja) | 2008-11-14 | 2009-11-13 | 細胞を操作するための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20110263001A1 (enExample) |
| EP (1) | EP2362912A1 (enExample) |
| JP (1) | JP2012508591A (enExample) |
| CN (1) | CN102369288A (enExample) |
| WO (1) | WO2011071476A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| ES2900277T3 (es) * | 2009-03-20 | 2022-03-16 | Mesoblast Inc | Producción de células pluripotentes reprogramadas |
| WO2011119942A1 (en) * | 2010-03-25 | 2011-09-29 | Vistagen Therapeutics, Inc. | Induction of ips cells using transient episomal vectors |
| AU2013212066B2 (en) * | 2012-01-26 | 2018-11-08 | Life Technologies Corporation | Methods for increasing the infectivity of viruses |
| SG11201404361UA (en) | 2012-01-26 | 2014-09-26 | Life Technologies Corp | Methods for increasing the infectivity of viruses |
| KR102055438B1 (ko) * | 2012-07-31 | 2019-12-19 | 에이지엑스 쎄라퓨틱스, 인크. | Hla g-변형된 세포 및 방법 |
| US9816074B2 (en) * | 2014-07-25 | 2017-11-14 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
| CN107106689A (zh) | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| US20180161455A1 (en) * | 2015-06-10 | 2018-06-14 | American Gene Technologies International, Inc. | Non-integrating viral delivery system and methods of use therof |
| WO2017007994A1 (en) | 2015-07-08 | 2017-01-12 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| US20190000940A1 (en) * | 2015-07-31 | 2019-01-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of aadc deficiency |
| CN111569090A (zh) | 2016-01-15 | 2020-08-25 | 美国基因技术国际有限公司 | 用于活化γ-δ T细胞的方法和组合物 |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖワクチン接種および免疫療法 |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| US11976292B2 (en) * | 2016-06-08 | 2024-05-07 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
| EP3481418A4 (en) | 2016-07-08 | 2020-03-11 | American Gene Technologies International Inc. | PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV |
| US11583562B2 (en) | 2016-07-21 | 2023-02-21 | American Gene Technologies International Inc. | Viral vectors for treating Parkinson's disease |
| CN110650673B (zh) | 2016-08-30 | 2024-04-09 | 加利福尼亚大学董事会 | 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统 |
| JP2020512815A (ja) | 2017-04-03 | 2020-04-30 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | フェニルケトン尿症を処置するための組成物および方法 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| WO2018232359A1 (en) | 2017-06-16 | 2018-12-20 | American Gene Technologies International Inc. | Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| CN109679994B (zh) * | 2018-12-13 | 2021-02-02 | 湖北汇智铭传生物科技股份有限公司 | 通过四环素诱导表达外源基因的游离载体及其构建方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5175385A (en) | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| NZ500843A (en) | 1995-06-07 | 2002-03-28 | Invitrogen Corp | A method of DNA recombination which is selectable to select for cells containing a product and against cells only harbouring the insert donor |
| US6143557A (en) | 1995-06-07 | 2000-11-07 | Life Technologies, Inc. | Recombination cloning using engineered recombination sites |
| FR2749857B1 (fr) * | 1996-06-12 | 1998-08-14 | Centre Nat Rech Scient | Generation de molecules replicatives in vivo |
| US5851808A (en) | 1997-02-28 | 1998-12-22 | Baylor College Of Medicine | Rapid subcloning using site-specific recombination |
| US5998204A (en) | 1997-03-14 | 1999-12-07 | The Regents Of The University Of California | Fluorescent protein sensors for detection of analytes |
| US7351578B2 (en) | 1999-12-10 | 2008-04-01 | Invitrogen Corp. | Use of multiple recombination sites with unique specificity in recombinational cloning |
| WO2000011155A1 (en) * | 1998-08-19 | 2000-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for genomic modification |
| US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| US8972161B1 (en) | 2005-11-17 | 2015-03-03 | Invent.Ly, Llc | Power management systems and devices |
| EP2103685A1 (en) * | 2008-03-20 | 2009-09-23 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Vectors and methods for generating vector-free induced pluripotent stem (iPS) cells using site-specific recombination |
| CA2726990C (en) * | 2008-06-04 | 2020-09-08 | Cellular Dynamics International, Inc. | Methods for the production of ips cells using extra-chromosomal vectors |
-
2009
- 2009-11-13 CN CN2009801532099A patent/CN102369288A/zh active Pending
- 2009-11-13 WO PCT/US2009/064488 patent/WO2011071476A2/en not_active Ceased
- 2009-11-13 US US12/618,700 patent/US20110263001A1/en not_active Abandoned
- 2009-11-13 EP EP09850164A patent/EP2362912A1/en not_active Withdrawn
- 2009-11-13 JP JP2011545349A patent/JP2012508591A/ja active Pending
-
2012
- 2012-08-09 US US13/571,141 patent/US20130040304A1/en not_active Abandoned
-
2015
- 2015-07-16 US US14/801,757 patent/US20160010113A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009282133B2 (en) | Methods for the Production of IPS Cells | |
| US9850499B2 (en) | Vectors and methods for the efficient generation of integration/transgene-free induced pluripotent stem cells from peripheral blood cells | |
| Eminli et al. | Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression | |
| Wang et al. | Reprogramming of mouse and human somatic cells by high‐performance engineered factors | |
| US20160076000A1 (en) | Polycistronic Vector for Human Induced Pluripotent Stem Cell Production | |
| CA2697621A1 (en) | Method of efficiently establishing induced pluripotent stem cells | |
| JP6189829B2 (ja) | Ｚｓｃａｎ４とｚｓｃａｎ４依存性遺伝子を利用した体細胞の直接的な再プログラム化 | |
| CN101743306A (zh) | 体细胞重编程 | |
| WO2010012077A1 (en) | Compositions, methods and kits for reprogramming somatic cells | |
| WO2011110051A1 (zh) | 用人工转录因子诱导产生多能干细胞 | |
| CN102369288A (zh) | 用于工程化细胞的组合物和方法 | |
| Lai et al. | Advancements in reprogramming strategies for the generation of induced pluripotent stem cells | |
| CN103739718B (zh) | 用于诱导多能干细胞的融合蛋白及其使用方法 | |
| JP2021048875A (ja) | 膵内分泌細胞の製造方法、及び分化転換剤 | |
| Pietronave et al. | Advances and applications of induced pluripotent stem cells | |
| WO2018214534A1 (en) | Artificial pou protein, method for preparing the same and use thereof | |
| US11834648B2 (en) | Human induced pluripotent stem cell lines for modeling Alzheimer's disease and usage thereof | |
| Takata et al. | Generation of iPS cells using a BacMam multigene expression system | |
| Worsdorfer et al. | Roadmap to cellular reprogramming–manipulating transcriptional networks with DNA, RNA, proteins and small molecules | |
| WO2010028019A2 (en) | Direct reprogramming of somatic cells using non-integrating vectors | |
| WO2010131747A1 (ja) | ウイルス産生細胞 | |
| CN107868126B (zh) | 多肽、制备方法及其应用 | |
| KR101456998B1 (ko) | 세포 간 단백질 전달을 이용한 역분화 줄기세포의 제조 방법 | |
| LU103239B1 (en) | Baculoviral vector system for delivery of heterologous gene products into mammalian cells | |
| Neshati et al. | Development of a lentivirus vector-based assay for non-destructive monitoring of cell fusion activity |